Effect of Subanesthetic Dose of Esketamine on Sleep Quality
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06773143, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT06773143
- Record updated
- 10 February 2025
- Original description
The goal of this clinical trial is to explore whether subanesthetic doses of esketamine can improve the sleep quality of patients undergoing modified radical mastectomy for breast cancer. In this study, 184 people are expected to participate from admission to three days after surgery.Read full original descriptionShow less
Effect of Subanesthetic Dose of Esketamine on Sleep Quality in Patients With Breast Cancer After Chemotherapy
The goal of this clinical trial is to explore whether subanesthetic doses of esketamine can improve the sleep quality of patients undergoing modified radical mastectomy for breast cancer. In this study, 184 people are expected to participate from admission to three days after surgery.
The process requires participants to cooperate with the completion of the digital rating scale, the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, the Hospital Anxiety and Depression Rating Scale, and the collection of venous blood for research indicators (IL-6, TNF-α, cor, BDNF).
If participants agree to participate in this study, the investigators will assign a unique identification number to each participant and create a medical record for participants.
One day before surgery, the investigators will conduct assessments using the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, and the Hospital Anxiety and Depression Scale, and collect approximately 6 mL of venous blood.
One day after surgery, the investigators will repeat the assessments using the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, and the Hospital Anxiety and Depression Scale. Additionally, the investigators will collect another 6 mL of venous blood and monitor the use of analgesics.
The investigators will follow up with participants three days after the surgery. During this follow-up, investigators will assess any sleep disturbances, administer the Hospital Anxiety and Depression Scale, and review the use of analgesics.
Inclusion: Patients diagnosed with breast cancer by pathology and immunohistochemistry; Patients receiving neoadjuvant chemotherapy; Age 18 to 65 years old; d) ; ASA grade Ⅰ - Ⅲ; BMI 18 to 30 kg/m2.
Exclusion: 1: Patients refuse to participate in the study; 2: BMI > 30 kg/m2; 3: Recent history of drug abuse; 4: Allergy to or contraindications to esketamine; 5: Cognitive dysfunction or inability to communicate; 6: Severe dysfunction of important organs such as liver and kidney function.